TrialThe Lancet. Oncology2019

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.

Andrew Davies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.